Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Collaborating Investigators

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences